|1.||Koukourakis, Michael I: 31 articles (08/2013 - 01/2002)|
|2.||Giatromanolaki, Alexandra: 16 articles (01/2013 - 01/2002)|
|3.||Grdina, David J: 15 articles (02/2013 - 01/2002)|
|4.||Murley, Jeffrey S: 14 articles (02/2013 - 01/2002)|
|5.||Sivridis, Efthimios: 14 articles (01/2013 - 01/2002)|
|6.||Kataoka, Yasushi: 11 articles (03/2009 - 01/2002)|
|7.||Movsas, Benjamin: 9 articles (06/2013 - 01/2002)|
|8.||Zhu, Hong-Li: 8 articles (01/2011 - 06/2005)|
|9.||Werner-Wasik, Maria: 7 articles (06/2013 - 01/2002)|
|10.||Komaki, Ritsuko: 7 articles (06/2013 - 04/2004)|
06/01/1982 - "The rapid clearance of WR2721 and poor vascularity of the intact tumors were thought to be responsible for the differential uptake and protection of normal tissues by WR2721."
03/01/1982 - "Protective effects of WR-2721 against radiation-induced injury of murine gut, testis, lung, and lung tumor nodules."
06/20/2011 - "Controversy exists regarding whether or not amifostine might reduce the efficacy of cancer treatment. "
11/01/2000 - "To determine if head and neck (H/N) cancer patients receiving daily amifostine during radiation therapy (RT) experienced clinical benefit (improvement in their ability to carry out normal functions with reduced discomfort) compared to nonamifostine treated patients. "
08/01/2012 - "We conducted a radiation dose-escalation trial for patients with diffuse, intrahepatic cancer treated with whole-liver radiation and intravenous amifostine. "
07/01/2000 - "The most important results in favor of amifostine were the reduction of intensity of cardiac, pulmonary and hepatic toxicity, and a significant reduction of frequency and severity of mucositis (P = 0. "
06/01/2000 - "A significant reduction of pharyngeal, esophageal, and rectal mucositis was noted in the amifostine arm (P <.04). "
06/01/1986 - "We have previously reported that Amifostine, a radioprotective agent, was effective in treating acute radiation mucositis in the head and neck region. "
01/01/2002 - "The authors have developed a rat RT model to examine the protective effects of amifostine after IV and subcutaneous (SC) administration in a mucositis model. "
03/01/2002 - "Ongoing trials are being conducted to determine the efficacy of amifostine in reducing radiation-induced mucositis and other toxicities. "
|3.||Head and Neck Neoplasms (Head and Neck Cancer)
02/01/2006 - "Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy."
12/01/2004 - "A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing."
01/01/2010 - "The aim of the present study was to explore the effects of amifostine on the radiation-induced apoptosis of peripheral blood lymphocytes from patients suffering head and neck cancer. "
02/01/2007 - "A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer."
03/01/2006 - "This randomized, double-blinded, placebo-controlled, phase III study evaluated the efficacy and safety of i.v. amifostine during radiochemotherapy for head-and-neck cancer. "
05/01/2006 - "In terms of xerostomia prevention, some clinical trials evaluating amifostine and intensity-modulated radiation therapy have shown positive results. "
11/15/2005 - "Amifostine administration was associated with a reduced incidence of Grade > or =2 xerostomia over 2 years of follow-up (p = 0.002), an increase in the proportion of patients with meaningful (>0.1 g) unstimulated saliva production at 24 months (p = 0.011), and reduced mouth dryness scores on a patient benefit questionnaire at 24 months (p < 0.001). "
03/01/2002 - "Furthermore, amifostine reduced the severity of late xerostomia, a side effect of RT with long-lasting consequences. "
01/01/2002 - "These data suggest that amifostine SC provided comparable protection against RT-induced acute xerostomia as amifostine intravenously."
01/01/2009 - "Amifostine versus placebo showed no statistically significant differences in the incidence of xerostomia (130 patients, two studies), the decrease of scintigraphically measured uptake of technetium-99m by salivary or submandibular glands at twelve months (80 patients, one study), and the reduction of blood pressure (130 patients, two studies). "
01/01/2002 - "The purpose of these 2 clinical trials was to investigate whether daily pretreatment with amifostine could reduce the incidence of esophagitis, and acute and late lung toxicity without affecting the antitumor efficacy of the treatment. "
05/01/2003 - "Pretreatment with amifostine showed a trend toward reducing the severity of esophagitis associated with concurrent chemoradiotherapy, but it did not reach statistical significance. "
06/01/2013 - "We report the long-term results of RTOG 9801, a randomized trial investigating the ability of amifostine, a radioprotector, to reduce chemoradiation-induced esophagitis. "
10/01/2008 - "Grade 3 esophagitis was reported in 30% of patients treated with amifostine and 9% of patients treated with epoetin-alpha (P = .059). "
01/01/2008 - "Twenty-four patients were enrolled: 18 patients were enrolled initially; 6 additional patients were enrolled following a protocol amendment designed to reduce the esophagitis by adding the radioprotectant amifostine. "
|10.||Mesna (Coenzyme M)
|2.||Drug Therapy (Chemotherapy)
|4.||Mammaplasty (Breast Reconstruction)
|5.||Modified Radical Mastectomy (Mastectomy, Modified)